VENTANA PD-L1(SP263) Assay Testing Centers

The only FDA approved test to predict a urothelial carcinoma patient’s response to IMFINZI™^* (durvalumab)

Using an approved assay to determine PD-L1 status for immunotherapy options is important. VENTANA PD-L1 (SP263) Assay equips pathologists by

• Identifying urothelial carcinoma patients most likely to benefit from IMFINZI™ (durvalumab)
• Providing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)

^{* IMFINZI™ (durvalumab) is a trademark of AstraZeneca Pharmaceutical Company. All rights reserved.}